Top Health-care stocks: <\/p>\n
JNJ: -0.02% <\/p>\n
PFE: flat <\/p>\n
ABT: flat <\/p>\n
MRK: flat <\/p>\n
AMGN: flat <\/p>\n
Health-care shares were generally unchanged in pre-market trading Wednesday. <\/p>\n
Redhill Biopharma's ( RDHL ) American depositary shares rose in Wednesday's pre-market session after the Israeli biopharmaceutical company said the UK Medicines and Healthcare Products Regulatory Agency has validated its marketing-authorization application for Bekinda, an extended-release, once-daily oral pill formulation of the antiemetic drug ondansetron to prevent chemotherapy and radiotherapy-induced nausea and vomiting. Shares were up 17% at $12.55 recently in the pre-market session Over the past 52 weeks, the stock has traded between $6.89 and $21. <\/p>\n
Sucampo Pharmaceuticals ( SCMP ) said Health Canada has accepted the company's New Drug Submission for AMITIZA 24 mcg capsules for the treatment of chronic idiopathic constipation in adults and opioid induced constipation in adults with chronic non-cancer pain. Shares were up 2.4% at $14.22 during Wednesday's pre-market trading session. Over the past 52 weeks, the stock has traded between $5.80 and $14.38. <\/p>\n
Meanwhile Mylan ( MYL ), a pharmaceutical company, said its subsidiary in India has been selected by the South African National Department of Health as one of the suppliers of antiretroviral medications used to treat HIV\/AIDS. The company was selected for a tender period beginning April 1, 2015 and lasting through March 31, 2018. Shares were unchanged during Wednesday's pre-market trading session. Over the past 52 weeks, the stock has traded between $41.97 and $59.60. <\/p>\n
<\/p>\n
Go here to read the rest: <\/p>\n
Health Care Sector Update for 12\/31\/2014: RDHL, SCMP, MYL<\/a><\/p>\n","protected":false},"excerpt":{"rendered":" Top Health-care stocks: JNJ: -0.02% PFE: flat ABT: flat MRK: flat AMGN: flat Health-care shares were generally unchanged in pre-market trading Wednesday. Redhill Biopharma's ( RDHL ) American depositary shares rose in Wednesday's pre-market session after the Israeli biopharmaceutical company said the UK Medicines and Healthcare Products Regulatory Agency has validated its marketing-authorization application for Bekinda, an extended-release, once-daily oral pill formulation of the antiemetic drug ondansetron to prevent chemotherapy and radiotherapy-induced nausea and vomiting. Shares were up 17% at $12.55 recently in the pre-market session Over the past 52 weeks, the stock has traded between $6.89 and $21. Continue reading